p
r
i
m
e
med
i
c
i
n
e
about
leadership
board of directors
scientific founders
team
investors
our partners
science
how prime editing works
scientific publications
references
media
press releases
in the news
scientific publications
careers
media
Press Releases
Filter By Year
10_19_21
Prime Medicine Announces Addition of Capabilities to Prime Editing Platform
Company applauds recent advances and ongoing development of Prime Editing
10_13_21
Prime Medicine Appoints Ann L. Lee as Chief Technical Officer
Industry veteran brings wealth of experience in process development and manufacturing for innovative medicines
7_13_21
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
Company is pioneering true “search and replace” gene editing
In the News
Filter By Year
9_22_21
Endpoints News
The Endpoints 11: They've got mad money and huge ambitions. It's time to go big or go home
Prime is selected to the Endpoints 11 2021 list
7_13_21
The Boston Globe
Startup Prime Medicine emerges with $315m to pioneer a new type of gene editing
The Cambridge company was founded by David Liu, a researcher at the Broad Institute of MIT and Harvard
7_13_21
Forbes
This Gene Editing Startup Raised $315 Million For A Next Generation Crispr Tool To Cure Rare Diseases
The gene editing technology Crispr may have been Nobel Prize-worthy, but Andrew Anzalone was convinced he could make it even better.
7_13_21
David Schenkein, GV
Prime Medicine’s Keith Gottesdiener on the Promise of Gene Editing
Keith and his team of physician-scientists are driven by their motivation to help people with genetic diseases.
7_13_21
Endpoints
David Liu takes the wraps off $315M launch round for Prime Medicine and new CRISPR tech that gave Bob Nelsen a 'holy crap' moment
Prime is emerging with ambitions to apply the new technology across the body,
7_13_21
Stat News
If everyone already knows about a new biotech startup, why does it ‘launch’?
On Tuesday, the belle of the launch ball was gene editing company Prime Medicine.
1
2
Scientific Publications
Filter By Year
11_2_21
BioRxiv
Programmable large DNA deletion, replacement, integration, and inversion with twin prime editing and site-specific recombinases
Andrew V. Anzalone, Xin D. Gao, Christopher J. Podracky, Andrew T. Nelson, Luke W. Koblan, Aditya Raguram, Jonathan M. Levy, Jaron A.M. Mercer & David R. Liu
10_4_21
Nature Biotechnology
Engineered pegRNAs improve prime editing efficiency
James W. Nelson, Peyton B. Randolph, Simon P. Shen, Kelcee A. Everette, Peter J. Chen, Andrew V. Anzalone, Meirui An, Gregory A. Newby, Jonathan C. Chen, Alvin Hsu & David R. Liu
6_22_20
Nature Biotechnology
Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Andrew V. Anzalone, Luke W. Koblan & David R. Liu
1_30_20
New England Journal of Medicine
Prime Time for Genome Editing?
Fyodor D. Urnov, Ph.D.
10_19_19
Nature
Search-and-replace genome editing without double-strand breaks or donor DNA
Andrew V. Anzalone, Peyton B. Randolph, Jessie R. Davis, Alexander A. Sousa, Luke W. Koblan, Jonathan M. Levy, Peter J. Chen, Christopher Wilson, Gregory A. Newby, Aditya Raguram & David R. Liu
prime_
About
Science
Media
Careers
Contact Us
|
Privacy Policy
|
Terms of Use
2021 Prime Medicine, Inc. PRIME MEDICINE
is a trademark of Prime Medicine, Inc.